“Extending our existing
partnership and securing further projects with AstraZeneca
is a high priority for us,” said Onno van de Stolpe,
Chief Executive Officer of Galapagos. “This latest
collaboration demonstrates the positive working relationship
and establishes our position as a proven partner specialized
in drug discovery services.”
“BioFocus DPI’s
commitment to delivering projects of high quality and on
time has been the main driver of AstraZeneca’s decision
to enter into a new agreement with BioFocus DPI. We have
been pleased with the level of progress thus far and expect
that BioFocus DPI’s expanded ADMET and predictive
drug discovery capabilities will be key contributors in
advancing this hit-to-lead program,” added Dr. Lars-Erik
Arvidsson, Vice President R&D Lund, AstraZeneca.
About Galapagos
Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam,
GLPGA; London AiM: GLPG) is a drug discovery company with
clinical and pre-clinical programs in bone and joint diseases,
cachexia, and menopausal hot flashes. Its division BioFocus
DPI offers a full suite of target-to-drug discovery products
and services to pharmaceutical and biotech companies, encompassing
target discovery and validation, screening and drug discovery
through to delivery of pre-clinical candidates. BioFocus
DPI also provides adenoviral reagents for rapid identification
and validation of novel drug targets, compound libraries
for drug screening as well as chemogenomics and ADMET database
products to select targets and compounds. Galapagos currently
employs 450 people and operates facilities in eight countries,
with global headquarters in Mechelen, Belgium. More information
about Galapagos and BioFocus DPI can be found at www.glpg.com
and www.biofocusdpi.com.
About AstraZeneca
AstraZeneca is a major international healthcare business
engaged in the research, development, manufacture and marketing
of prescription pharmaceuticals and the supply of healthcare
services. It is one of the world's leading pharmaceutical
companies with healthcare sales of $26.47 billion and leading
positions in sales of gastrointestinal, cardiovascular,
neuroscience, respiratory, oncology and infection products.
AstraZeneca is listed in the Dow Jones Sustainability Index
(Global) as well as the FTSE4 Good Index. More information
about AstraZeneca can be found at www.astrazeneca.com.
CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 290 980 28
ir@glpg.com
This release may contain forward-looking statements,
including, without limitation, statements containing the
words “believes,” “anticipates,”
“expects,” “intends,” “plans,”
“seeks,” “estimates,” “may,”
“will,” “could,” “stands to,”
and “continues,” as well as similar expressions.
Such forward-looking statements may involve known and unknown
risks, uncertainties and other factors which might cause
the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial
conditions, performance or achievements expressed or implied
by such forward-looking statements. Given these uncertainties,
the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements
speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any
such forward-looking statements in this document to reflect
any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any
such statement is based, unless required by law or regulation.
